4/A: Verrica Pharmaceuticals CFO Corrects Stock Award Reporting in Amended SEC Filing
SEC Filing
Verrica Pharmaceuticals' CFO, Terry Kohler, files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) awarded, following the first commercial sale of VP-102.
Summary
- Terry Kohler, CFO of Verrica Pharmaceuticals, filed an amended SEC Form 4/A on February 6, 2025, to correct a previous filing regarding restricted stock units (RSUs).
- The original Form 4, filed on August 28, 2023, incorrectly reported the number of RSUs awarded.
- The amendment clarifies that 125,000 RSUs were awarded, with 50% vesting upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vesting on August 24, 2024.
- The initial filing only reported the number of shares that vested on August 24, 2023, leading to the correction.
Sentiment
Score: 7
Explanation: The document is a routine correction of a previous filing, indicating standard corporate governance procedures. There is no indication of positive or negative sentiment, but the correction itself is a positive sign of transparency.
Negatives
- The initial Form 4 filing contained an error in reporting the number of RSUs awarded.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 08/24/2023 | Date of earliest transaction and first commercial sale of VP-102; 50% of RSUs vested. |
| 08/28/2023 | Date of original Form 4 filing (incorrect). |
| 08/24/2024 | Date of vesting for the remaining 50% of RSUs. |
| 02/06/2025 | Date of amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.